An­a­lysts start to sort out which bio­phar­ma com­pa­nies’ R&D plans are most threat­ened by a pan­dem­ic

With the pan­dem­ic cap­tur­ing head­lines around the world, one of the big ques­tions in bio­phar­ma is whether or not the in­evitable dis­rup­tions caused by the out­break will rip­ple — or tear — through drug R&D plans.

So far, there have been few re­ports of any in­ter­rup­tions in clin­i­cal tri­als out­side of Chi­na, where the hos­pi­tal-based sys­tem of drug re­search is tak­ing an ob­vi­ous beat­ing as peo­ple steer clear of hos­pi­tals. But the prospect that the pan­dem­ic will in­evitably have an im­pact is hard to ig­nore.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Recon Strategy

Boston, MA, USA